Find Academic Supervisors

Professor Ananya Choudhury serves as Chair and Honorary Consultant in Clinical Oncology at the University of Manchester, where she is also Co-Group Leader of the Translational Radiobiology Group within the Division of Cancer Sciences. She joined The Christie NHS Foundation Trust in 2008, specializing in urology and sarcoma, and has since focused on radiotherapy-related research in prostate and bladder cancers. Professor Choudhury is clinical lead for advanced radiotherapy, including the groundbreaking MRLinac project, and plays a key role in national radiotherapy research initiatives. Professor Choudhury earned her BA (Hons) in 1993, MB. BChir (Cantab) in 1995, and MA (Cantab) in 1997 from Trinity College, Cambridge. She completed her Clinical Oncology training at the Yorkshire Deanery from 2000-2008, during which she earned her MRCP in 2000 and F.R.C.R in 2004. She completed her PhD in 2008 through the University of Leeds and Princess Margaret Hospital in Toronto, Canada, where she studied the molecular epidemiology of DNA double strand break repair in bladder cancer. Professor Choudhury's research program focuses on optimizing and personalizing radiotherapy using advanced imaging technology to deliver high doses while minimizing side effects. Her work centers on prostate and bladder cancers, with particular interest in predictive biomarkers, hypoxia, and the integration of magnetic resonance imaging to improve treatment precision. She has pioneered research in radiotherapy dose optimization, biomarker development, and the identification of patients who would benefit most from different treatment approaches. Her extensive publication record demonstrates a strong focus on radiation therapy, particularly in genitourinary cancers. Recent work explores MRI-guided radiotherapy, hypoxia biomarkers, and personalized treatment approaches across multiple cancer types. She has made significant contributions to understanding how imaging technology can improve radiotherapy precision and effectiveness while reducing side effects, with several publications appearing in top journals through 2025. Professor Choudhury has received multiple prestigious awards recognizing her contributions to the field: Cancer Research-UK/Royal College of Radiologists Clinical Training Fellowship (2005) Fellowship for the 10th ECCO-AACR-ASCO Workshop on Methods in Clinical Cancer Research (2007) Outstanding Contribution, Greater Manchester Clinical Research Awards (2017) RCR Research Fellowship (2005) Research Fellowship, Princess Margaret Hospital, Toronto (2004) Professor Choudhury has supervised numerous doctoral and master's students across multiple cancer types, with current students expected to complete through 2024. She is Principal Investigator on multiple research grants, including 'Measuring tumour radioresistance to improve radiotherapy outcomes' and the 'MAESTRO Programme' as part of CRUK RadNet. Her research program is supported by significant funding from NIHR Manchester Biomedical Research Centre and other major funding bodies. As Co-Group Leader of the Translational Radiobiology Group, Professor Choudhury collaborates extensively with leading researchers including Peter Hoskin, Catharine West, Corinne Faivre-Finn, and Marcel van Herk. Her team is at the forefront of integrating advanced imaging with radiotherapy to improve cancer treatment outcomes, with active projects spanning from basic radiobiology to clinical implementation of novel radiotherapy techniques.

• Radiation Therapy
• Prostate Cancer
• Bladder Cancer
• +9 more

Brian Kavanagh, MD, MPH is a Professor and Department Chair of Radiation Oncology at the University of Colorado Anschutz Medical Campus School of Medicine. He serves as Department Chair and maintains clinical practice at multiple UCHealth locations including the University of Colorado Cancer Center, Cherry Creek Medical Center, Longs Peak Medical Center, and the Rocky Mountain Gamma Knife Center. His leadership extends to serving as Chair of the American Society for Radiation Oncology since 2017. MD, Tulane University School of Medicine (1988) MPH, Tulane University (1988) BSE, Tulane University (LA) (1984) Internship: Tulane University Program (1989) Residency: Duke University Hospital Program, Radiation Oncology (1993) Dr. Kavanagh's research primarily focuses on stereotactic body radiation therapy (SBRT), functional lung avoidance radiation therapy using 4DCT-ventilation imaging, and treatment of brain metastases from oncogene-driven lung cancers. His work bridges clinical practice, medical physics innovation, and outcomes research, with particular emphasis on optimizing radiation therapy techniques while minimizing toxicity. Recent publications demonstrate his leadership in developing novel approaches to image-guided radiation therapy, including antiscatter grid technology for CBCT imaging and functional avoidance techniques for lung cancer treatment. Analysis of Dr. Kavanagh's recent publications (2019-2024) reveals a strong focus on precision radiation therapy for lung cancer and brain metastases. His research spans technical innovations in medical physics (such as 2D antiscatter grid development), clinical trials evaluating functional avoidance radiation therapy, and studies examining outcomes for patients with oncogene-driven cancers. A significant portion of his work addresses the integration of radiation therapy with targeted therapies for lung cancer with brain metastases, reflecting the evolving treatment paradigms in this field. Top Doctor, 5280 Magazine (2023) Dr. Kavanagh has been instrumental in developing national radiation oncology curriculum frameworks through stakeholder consensus processes. His leadership in the American Society for Radiation Oncology has positioned him to influence practice guidelines and educational standards in the field. His research has been supported through multi-institutional clinical trials and collaborations with major cancer centers across the United States. Dr. Kavanagh leads research efforts in the Rocky Mountain Gamma Knife Center and contributes to the University of Colorado Cancer Center's radiation oncology program. His work with 4DCT-ventilation imaging has established a clinical research program focused on functional avoidance radiation therapy, which aims to preserve lung function while effectively treating tumors.

• Radiation Oncology
• Stereotactic Body Radiation Therapy
• Functional Lung Avoidance Radiation Therapy
• +7 more

Haoming Qiu, M.D. serves as an Associate Professor in the Department of Radiation Oncology at the University of Rochester School of Medicine and Dentistry. He practices clinically at both Wilmot Cancer Center in Rochester and Sands Cancer Center in Canandaigua, providing radiation oncology services for gastrointestinal, lung, and prostate cancers. Board-certified by the American Board of Radiology, Dr. Qiu specializes in advanced radiotherapy techniques including external beam radiation and radiopharmaceutical therapies. Education: MD, Johns Hopkins University (2011) Residency in Radiation Oncology, University of Rochester Medical Center (2013-2016) Residency in Radiation Oncology, Loyola University Medical Center (2012-2013) Internship in Internal Medicine, Sinai Hospital of Baltimore (2011-2012) Research Focus: Dr. Qiu's work centers on optimizing radiation therapy for gastrointestinal malignancies, prostate cancer, and neuroendocrine tumors. His investigations into theranostics explore novel applications of Lutathera for neuroendocrine tumors, Pluvicto for prostate cancer, and Therasphere for liver cancers. Current research emphasizes combining stereotactic body radiotherapy with immunotherapeutic agents to overcome treatment resistance in pancreatic and rectal cancers. Publication Trends: Recent publications (2023-2025) reveal a strategic shift toward adaptive radiotherapy techniques for pelvic malignancies and immunoradiotherapy combinations. His work demonstrates growing emphasis on modulating tumor immune microenvironments through radiation, particularly in pancreatic and rectal cancers. The integration of mRNA nanotechnology with SBRT represents a cutting-edge frontier in his research portfolio. Scientific Recognition: Roentgen Resident/Fellow Research Award (2015) Excellence in Medical Student Research (2011) Clinical Leadership: Dr. Qiu directs multiple clinical trials at the University of Rochester focusing on radiopharmaceutical applications and adaptive radiotherapy protocols. His patient-centered approach is reflected in consistently high patient satisfaction scores (4.9/5 stars) across communication, empathy, and treatment explanation metrics. Care Coordination: As part of the Wilmot Cancer Center and Sands Cancer Center teams, Dr. Qiu collaborates with multidisciplinary groups including medical oncologists, surgeons, and radiologists to deliver integrated cancer care through Accountable Health Partners network.

• Radiation Oncology
• Gastrointestinal Cancers
• Lung Cancer
• +5 more

Knut Håkon Hole is an Associate Professor at the University of Oslo's Department of Radiology and Nuclear Medicine. His research focuses on diagnostic imaging applications in oncology, particularly in prostate and rectal cancers. He specializes in MRI, PET, and radiogenomics techniques to assess tumor biology, treatment response, and recurrence. Expertise: Prostate cancer imaging, neoadjuvant therapy response, tumor hypoxia, and imaging biomarkers Key affiliations: Oslo University Hospital (Rikshospitalet), Radium Hospital Research interests include: Developing MRI and PET protocols for cancer staging and recurrence detection Integrating imaging with genomic data (radiogenomics) Optimizing therapeutic approaches using imaging biomarkers Recent work highlights: Prostate cancer radiogenomics and hypoxia biomarkers (2024) MRI/PET comparisons for tumor localization (2021-2023) Neoadjuvant therapy response assessment in rectal and breast cancers (2020-2023) Publications span over 50 peer-reviewed articles with a focus on translational imaging research. Collaborates extensively with oncology and urology teams.

• Radiology
• Oncology
• Medical Imaging
• +4 more

Amar U. Kishan, MD , a tenure Professor at the David Geffen School of Medicine, UCLA , serves as Executive Vice Chair for the Department of Radiation Oncology and as Chief of the Genitourinary Service since 2019. His clinical expertise focuses on radiation treatment of prostate and bladder cancers , with pioneering work in stereotactic body radiation therapy (SBRT) and image-guided radiotherapy . Dr. Kishan graduated magna cum laude from Harvard Medical School after dual BA degrees at UC Berkeley in Molecular and Cell Biology and Public Health, followed by residency at UCLA and internship at Scripps Mercy Hospital . Education : Harvard Medical School (MD, 2012), UC Berkeley (BA in Molecular/Cell Biology & Public Health) Awards : Leonard Tow Humanism in Medicine (2021), UCLA Exceptional Physician (2024), Super Doctors® Rising Stars (2020-2024) Dr. Kishan leads translational research connecting radiation oncology with genitourinary cancer biology. His 310+ publications in journals like JAMA , Lancet Oncology , and European Urology emphasize radiation technology innovations , including MRI-guided SBRT and adaptive radiation therapy. Key trials he spearheads include ILLUSION (CT-guided SBRT) and HEATWAVE (apalutamide + SBRT). Major funding sources include National Institutes of Health , Department of Defense , and Prostate Cancer Foundation . His work has redefined prostate cancer treatment paradigms , demonstrating that high-dose radiation can match surgery in aggression cases, while multi-modal approaches improve survival rates. Dr. Kishan also contributes to re-irradiation protocols and radioresistance proteogenomics , advancing precision oncology. Key Grants : NIH, DoD, PCF, ASTRO Clinical Trials : ILLUSION, HEATWAVE, PET imaging-based radiation targeting

• Translational Research
• Clinical Outcomes Research
• Advanced Radiation Technologies
• +5 more

Pouyan Rezapoor is a Doctoral Researcher affiliated with Aalto University's Department of Electronics and Nanoengineering. His research focuses on terahertz imaging systems, medical physics, and computational modeling for cancer treatment. Research areas: Terahertz imaging, MRI-guided radiotherapy, and electromagnetic wave propagation Key collaborations: Zachary Taylor Group, Dan Ruan, and international researchers in biomedical engineering Current work examines radiation toxicity prediction in prostate cancer patients and optical system design for THz imaging. Recent publications analyze telecentric lens systems, cross-polarization effects, and computational methods to address feature correlation in clinical data.

• Terahertz Imaging
• Medical Physics
• Computational Oncology
• +2 more

Dr. Patrick Oh serves as an Assistant Professor of Therapeutic Radiology at Yale School of Medicine, practicing as a radiation oncologist at Yale Cancer Center and Smilow Cancer Hospital. He specializes in treating thoracic and genitourinary cancers, as well as hematologic, cutaneous, and metastatic malignancies with an emphasis on individualized, holistic patient care to optimize both disease outcomes and quality of life. His educational background includes: BS from Duke University MD from Stony Brook University School of Medicine Preliminary Medicine Intern at NYU Langone Hospital-Long Island Resident Physician in Radiation Oncology at Yale New Haven Hospital (served as Chief Resident) Gamma Knife Cranial Radiosurgery Certification from Cleveland Clinic Dr. Oh's research focuses on reducing radiation-induced toxicities, particularly cardiopulmonary effects, and expanding the role of radiation therapy across various cancer types. His clinical expertise encompasses advanced radiotherapy techniques including stereotactic body radiation therapy (SBRT), intensity-modulated radiation therapy (IMRT/VMAT), and image-guided radiation therapy (IGRT). Professional recognition includes: RSNA Roentgen Resident Research Award (awarded June 7, 2025) Dr. Oh is dedicated to medical education, actively mentoring residents and medical students with emphasis on communication skills and patient-centered care. He maintains active professional memberships including the American Society for Therapeutic Radiology (2021-present), where he serves on the Board of the Korean American Society for Therapeutic Radiation Oncology (2024-present), and the American Society of Clinical Oncology (2018-present). He treats both adult and pediatric patients and accepts new appointments through Yale Medicine.

• Radiation Oncology
• Therapeutic Radiology
• Cancer Treatment
• +8 more

Sameer Nath, MD, is an Associate Professor in the Department of Radiation Oncology at the University of Colorado Anschutz Medical Campus School of Medicine. He holds leadership roles as Vice Chair of Clinical Affairs, Clinical Practice Director at Anschutz Medical Campus, and Medical Director of Radiation Oncology at Highlands Ranch Hospital. Dr. Nath is board-certified in Radiation Oncology and practices at UCHealth Radiation Oncology and Rocky Mountain Gamma Knife Center. MD: University of California, San Diego School of Medicine (2010) Internship: University of California, San Diego (2011) Residency: Yale-New Haven Medical Center, Chief Resident in Radiation Oncology (2015) His research focuses on radiation therapy applications for prostate and lung cancers, brain metastases management, and immunotherapy-radiation combinations. He has pioneered work in stereotactic body radiation therapy (SBRT), tumor hypoxia, radiation pneumonitis prevention, and medical imaging innovations for treatment planning. Recent publications examine oligoprogressive prostate cancer management, radiation oncology nurse education, and deep learning applications in patient positioning. Dr. Nath's 15 most recent publications (2024-2017) demonstrate expertise in prostate cancer (4 articles), lung cancer (4 articles), brain metastases (4 articles), and medical imaging/education (3 articles). Key research themes include SBRT optimization, immunotherapy response monitoring, and radiation toxicity management. American Society of Radiation Oncology (ASTRO) Member Practice locations: UCHealth Radiation Oncology - Anschutz Medical Campus (Aurora, CO) and Rocky Mountain Gamma Knife Center - Anschutz Medical Campus (Aurora, CO) Hospital affiliations: UCHealth Highlands Ranch Hospital and University of Colorado Hospital

• Radiation Oncology
• Prostate Cancer
• Lung Cancer
• +3 more

Professor Daniel Galvão is a leading academic in exercise oncology at Edith Cowan University (ECU), Australia. He serves as Director of the Exercise Medicine Research Institute and holds a Professorship in Exercise and Sports Science within the School of Medical and Health Sciences. His research focuses on optimizing exercise interventions to mitigate treatment-related toxicities and improve outcomes for cancer patients, particularly those with prostate cancer. Galvão has secured over $26 million in grants from bodies like the NHMRC, Movember Foundation, and Cancer Australia, supporting multidisciplinary trials and survivorship programs. Education: PhD (Edith Cowan University, 2006), Master of Applied Science in Clinical Exercise Science (University of Queensland, 2003). His career includes roles as Co-Director of ECU’s Health and Wellness Institute and Fellowships with the American College of Sports Medicine and Exercise and Sports Science Australia. Research emphasizes exercise as medicine in oncology, with over 200 peer-reviewed publications. Key contributions include guidelines for exercise in cancer patients and landmark trials like ERADICATE (prostate cancer radiotherapy adjuncts) and TelEX (weight management for prostate cancer). Notable awards include the 2021 Asian Pacific Prostate Cancer Conference Best Poster, 2014 Edith Cowan Vice-Chancellor’s Award, and 2007 ESSA PhD Medal. He chairs national research committees and reviews for high-impact journals like Journal of Clinical Oncology and European Urology . Current initiatives include nationwide exercise programs for prostate cancer survivors and translational research on myokine mechanisms in cancer suppression. His work bridges clinical practice with evidence-based interventions to enhance patient quality of life and survival outcomes.

• Exercise Oncology
• Cancer Rehabilitation
• Prostate Cancer Treatment
• +3 more

Dr. Jason Chan is an Associate Professor in the Department of Radiation Oncology at the University of California, San Francisco (UCSF) School of Medicine. His clinical practice focuses on the treatment of head and neck, skull base, cutaneous, and thoracic malignancies, offering advanced techniques including Cyberknife radiosurgery and high-dose-rate brachytherapy for both initial and repeat radiotherapy. Dr. Chan received his medical degree from Brown University and completed his Internal Medicine internship at Kaiser Permanente San Francisco followed by a residency in Radiation Oncology at UCSF. His academic journey has positioned him as a prominent researcher in head and neck oncology, with particular expertise in HPV-associated oropharyngeal cancer, nasopharyngeal cancer, lung cancer, thyroid cancer, and cutaneous malignancies. His research spans multiple domains including radiation therapy optimization, AI applications in radiation oncology, cancer outcomes research, and translational studies. Dr. Chan's work frequently addresses critical questions in treatment de-escalation for HPV-positive cancers, reirradiation techniques, and health disparities in cancer outcomes. Recent publications demonstrate his leadership in investigating swallowing function outcomes, dosimetric analysis of brachytherapy, and the impact of socioeconomic factors on nasopharyngeal carcinoma outcomes. Dr. Chan actively participates in numerous clinical trials and translational studies, particularly in head and neck and lung cancers. His collaborative approach is evident in his extensive co-authorship network with colleagues at UCSF and other institutions. His work bridges clinical practice with technological innovation, especially in the application of artificial intelligence to radiation therapy planning and delivery. Dr. Chan's research portfolio reflects a commitment to improving both the precision and accessibility of cancer care while addressing significant clinical challenges in radiation oncology.

• Head and Neck Cancer
• Radiation Oncology
• HPV-associated Oropharyngeal Cancer
• +7 more

Francesca Ieva serves as Associate Head of the Health Data Science Centre at Human Technopole and Associate Professor of Statistics at the Politecnico di Milano, where she leads the MOX - Modeling and Scientific Computing laboratory within the Department of Mathematics. She also co-leads the Di Angelantonio & Ieva Group, a collaborative research team focused on integrating molecular data with clinical information to advance precision medicine. Dr. Ieva received her PhD in Mathematical Models and Methods for Engineering in 2012. Her academic journey has positioned her at the forefront of health data science, bridging statistical methodology with biomedical applications. Her research focuses on statistical learning in biomedical sciences, with particular emphasis on developing advanced models for integrating complex clinical data to inform predictions in clinical decision-making. Francesca's work spans multiple domains including: Development of novel survival analysis techniques for healthcare applications Integration of DNA methylation data for cardiovascular risk prediction Application of machine learning to clinical pathway analysis in mental health Innovative approaches to polygenic risk scoring incorporating SNP interactions Development of radiomics models for cancer prognosis and treatment response Analysis of Dr. Ieva's recent publications reveals a strong trend toward federated learning approaches in healthcare data analysis, reflecting growing concerns about data privacy while maintaining analytical power. Her work increasingly integrates multiple data types (genomic, epigenetic, imaging, and clinical records) to create more comprehensive patient profiles for precision medicine applications. A notable pattern is her focus on translating complex statistical models into clinically actionable tools that can directly inform patient care and healthcare policy decisions. As Associate Head of the Health Data Science Centre at Human Technopole, Dr. Ieva oversees a research group comprising epidemiologists, statisticians, and data scientists working collaboratively to bridge the gap between genotype and phenotype. The Di Angelantonio & Ieva Group develops innovative studies that integrate biomolecular data with medical records, imaging, and portable medical device data. Her team utilizes both existing healthcare data and newly generated population-based studies, applying novel analytical methods that integrate clinical epidemiology with health research to improve data interpretation. Dr. Ieva actively mentors several PhD students including Andrea Lampis, Katherine Marie Logan, Alessia Mapelli, Michela Carlotta Massi, and Andrea Mario Vergani. Her research has been supported by collaborations with major healthcare institutions and likely receives funding from research councils and health technology initiatives, though specific grant details are not provided in the available information.

• Biostatistics
• Health Data Science
• Statistical Learning
• +5 more

Andrew Jirasek is a Professor at the Irving K. Barber Faculty of Science , University of British Columbia Okanagan , and serves as the Associate Dean for Graduate and Postdoctoral Training . He leads the Analytics in Medical Sciences (AiMS) Institute with a focus on Medical Physics and Radiation Oncology Physics , particularly utilizing Raman spectroscopy and 3D radiation dosimetry for cancer treatment verification. PhD from University of British Columbia His research involves developing polymer gel dosimeters for 3D radiation dose verification in complex therapies like volumetric modulated arc therapy (VMAT) , collaborating across physics, oncology, and engineering . He also investigates optical technologies to monitor biological responses during radiotherapy using Raman spectroscopy with machine learning for data analysis. Recent publications highlight advancements in 3D gel dosimetry , Raman spectroscopy for metabolic profiling , and iterative image reconstruction algorithms . His work spans dosimeter technology development , radiation therapy quality assurance , and clinical applicability studies for novel treatment verification methods.

• Medical Physics
• Radiation Oncology Physics
• Raman Spectroscopy
• +3 more

Jonathan Mamou is a Professor of Electrical Engineering in Radiology at Weill Cornell Medical College since 2024. His research focuses on quantitative ultrasound imaging, biomedical engineering, medical imaging, and acoustic microscopy. Ph.D., University of Illinois (2005) M.S., University of Illinois (2002) B.S., Telecom Paris (2000) His research bridges electrical engineering and radiology, developing advanced ultrasound techniques for medical diagnostics. Key areas include quantitative acoustic microscopy , biomechanical tissue analysis , and machine learning in ultrasound imaging . Recent work spans prostate cancer detection , placental microstructure characterization , and myopia-related scleral changes . His publications (2025–2023) highlight innovations in high-frequency ultrasound for ophthalmology, quantitative imaging for cancer diagnostics, and quantum-driven resolution enhancement in acoustic microscopy. Grants from the Melanoma Research Alliance , National Institute of Biomedical Imaging & Bioengineering , and Stand Up To Cancer support his work on pancreatic cancer screening , interstitial lung diseases , and radiotherapy toxicity assessment .

• Quantitative Ultrasound Imaging
• Biomedical Engineering
• Medical Imaging
• +5 more

Els Goetghebeur is a Full Professor at Ghent University's Department of Applied Mathematics, Computer Science and Statistics. She chairs the UGent Expert Center for Statistics and serves as Chief-Editor of Statistics in Medicine , while leading the causal inference group within the STRATOS initiative. Her research emphasizes causal inference, survival analysis, and quality of care assessment in biomedical contexts. University: Ghent University Department: Applied Mathematics, Computer Science and Statistics Leadership Roles: Chair of UGent Expert Center for Statistics, Chief-Editor of Statistics in Medicine, Lead of STRATOS Causal Inference Group Her work spans methodological developments in causal inference and survival analysis, applied to biomedical challenges like cancer outcomes, transplant medicine, and tuberculosis diagnostics. Recent publications focus on propensity score methods, latent class analysis, and patient-reported outcome modeling across diverse clinical trials. Key trends in her research include: Improving causal inference techniques in observational studies Advancing survival analysis methods for complex clinical data Standardizing statistical practices in biomedical research through editorial leadership Developing frameworks for handling missing data in patient-reported outcomes Contributing to multicenter clinical trial designs for prostate cancer and solid tumors

• Biostatistics
• Causal Inference
• Quality of Care
• +2 more

Sara Margareta Cecilia Pilskog serves as an Associate Professor in the Department of Physics and Technology at the University of Bergen, Norway, with dual affiliation at Haukeland University Hospital's Department of Cancer Treatment and Medical Physics. Her research bridges theoretical medical physics and clinical oncology applications, focusing on precision radiotherapy techniques and biological optimization. Her primary research interests center on proton therapy innovation, where she investigates biological optimization strategies using linear energy transfer (LET) and relative biological effectiveness (RBE) modeling. She develops adaptive radiotherapy frameworks to address inter-fractional motion in pelvic cancers, particularly prostate and rectal malignancies. Her work also pioneers neutron-based in-vivo range verification systems and statistical deformation models for dose accumulation. Current projects emphasize reducing treatment margins through anatomical robustness and optimizing biological dose distributions for organ sparing. Analysis of her 15 most recent publications reveals a dominant focus on improving proton therapy precision for pelvic cancers through biological modeling and motion management. Approximately 70% of her work addresses prostate cancer applications, with significant contributions to adaptive strategies for inter-fractional changes and biological optimization techniques. Her research consistently employs Monte Carlo simulations (particularly FLUKA) and clinical data analysis to translate theoretical models into clinically viable solutions. No scientific awards were documented in the provided materials. While specific advising details remain unreported, her collaborative patterns indicate active mentorship within the University of Bergen's medical physics research ecosystem. Her publications consistently involve junior co-authors from clinical physics teams at Haukeland University Hospital, suggesting hands-on supervision of technical staff and research fellows in radiotherapy innovation projects. Grant funding appears primarily channeled through institutional hospital-university partnerships focused on clinical translation of advanced radiotherapy techniques. Dr. Pilskog operates within the University of Bergen's medical physics research cluster that maintains close operational ties to Haukeland University Hospital's radiotherapy department. This integrated academic-clinical environment enables direct implementation of her research on adaptive proton therapy and biological optimization into clinical workflows, with particular emphasis on pelvic cancer treatment protocols. The team utilizes advanced Monte Carlo simulation platforms and clinical treatment planning systems to develop and validate next-generation radiotherapy approaches.

• Medical Physics
• Radiation Oncology
• Proton Therapy
• +3 more